Share Price and Basic Stock Data
Last Updated: February 6, 2026, 8:28 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Banka Bioloo Ltd operates in the infrastructure sector, focusing on sustainable solutions. The company’s share price stood at ₹60.8, with a market capitalization of ₹66.4 Cr. Over the past few quarters, Banka Bioloo’s revenue trends have shown volatility. For instance, sales in September 2022 were ₹12.36 Cr, which decreased to ₹8.18 Cr by March 2023, before recovering to ₹11.45 Cr in September 2023. The most recent quarter, December 2023, recorded sales of ₹13.96 Cr, indicating a positive trajectory. However, the trailing twelve months (TTM) sales were reported at ₹53.03 Cr, highlighting a need for sustained growth to meet industry expectations. The company’s operating profit margin (OPM) has fluctuated significantly, with a negative OPM of -0.08% at present, reflecting challenges in maintaining profitability amidst operational costs. This inconsistency in sales and profitability indicates the necessity for improved operational efficiency to stabilize revenue streams.
Profitability and Efficiency Metrics
The profitability metrics of Banka Bioloo reveal significant challenges. The company’s net profit for the fiscal year ending March 2025 was reported at a loss of ₹8.91 Cr, translating to an earnings per share (EPS) of -₹8.21. This decline from a net profit of ₹2.54 Cr in March 2023 and an EPS of ₹2.34 underscores a deteriorating financial performance. The operating profit has also significantly declined to -₹2.85 Cr for the same period, with an operating profit margin of -5.26%. Additionally, the interest coverage ratio (ICR) stood at -0.67x, indicating that the company is not generating sufficient operating income to cover its interest expenses, posing a risk to financial stability. The cash conversion cycle (CCC) is reported at 187.28 days, suggesting inefficiencies in managing receivables and inventory, which further complicates the profitability landscape.
Balance Sheet Strength and Financial Ratios
Banka Bioloo’s balance sheet presents a mixed picture. As of September 2025, total assets stood at ₹80.12 Cr, while total liabilities were ₹82.16 Cr, leading to a negative net worth. The company’s borrowings increased to ₹32.39 Cr, with a debt-to-equity ratio of 1.09x, indicating a reliance on debt financing, which is concerning given the current profitability issues. Reserves have decreased to ₹19.74 Cr, down from ₹29.25 Cr in March 2023, reflecting challenges in retaining earnings due to ongoing losses. The current ratio of 1.41x suggests that the company can cover its short-term liabilities, but the quick ratio of 1.25x indicates potential liquidity concerns. Furthermore, return on equity (ROE) is reported at 24.2%, which is relatively strong; however, the return on capital employed (ROCE) of 7.61% is low compared to typical industry standards, indicating inefficiency in utilizing capital.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Banka Bioloo shows a significant concentration of ownership among promoters, holding 52.23% of shares. This stability among promoters could be seen as a positive indicator for investor confidence. However, the absence of foreign institutional investors (FIIs) and the relatively low public holding of 47.77% may raise concerns about broader appeal and market perception. The number of shareholders has fluctuated, with a peak of 6,265 in March 2024, declining to 5,637 by September 2025. This trend may indicate waning interest from retail investors amidst financial struggles. The lack of dividends in recent years further reflects the company’s focus on retaining cash to manage its operational challenges. Overall, while promoter support is a strength, the lack of diversification in ownership could deter potential institutional interest.
Outlook, Risks, and Final Insight
Moving forward, Banka Bioloo faces both opportunities and significant risks. The ongoing volatility in revenue and profitability highlights the need for strategic initiatives to enhance operational efficiency and reduce costs. The company must focus on improving its cash conversion cycle and managing its debt levels to mitigate financial strain. Risks include high operational costs and reliance on debt financing, which could exacerbate losses if sales do not stabilize. Conversely, strengthening its market position through innovative product offerings and operational improvements could provide a pathway for recovery. If the company successfully navigates these challenges, it could regain investor confidence and improve its financial metrics. However, failure to address these operational inefficiencies may lead to further declines in profitability and shareholder value.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genus Prime Infra Ltd | 48.0 Cr. | 32.1 | 32.1/16.3 | 107 | 157 | 0.00 % | 0.06 % | 0.09 % | 2.00 |
| Ekansh Concepts Ltd | 293 Cr. | 193 | 308/96.4 | 182 | 33.3 | 0.00 % | 4.41 % | 1.88 % | 10.0 |
| Dhruv Consultancy Services Ltd | 65.4 Cr. | 34.6 | 128/34.0 | 9.68 | 55.9 | 0.58 % | 11.3 % | 8.19 % | 10.0 |
| Crane Infrastructure Ltd | 10.2 Cr. | 14.1 | 24.0/13.6 | 22.7 | 41.7 | 0.00 % | 2.84 % | 2.21 % | 10.0 |
| Brahmaputra Infrastructure Ltd | 371 Cr. | 128 | 136/36.2 | 7.10 | 109 | 0.00 % | 10.8 % | 11.0 % | 10.0 |
| Industry Average | 1,536.30 Cr | 114.68 | 34.15 | 90.74 | 0.20% | 9.84% | 14.41% | 8.15 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12.36 | 10.71 | 8.18 | 8.28 | 11.45 | 13.96 | 16.31 | 12.89 | 12.41 | 14.04 | 14.84 | 11.14 | 13.01 |
| Expenses | 10.85 | 8.49 | 7.18 | 9.79 | 9.16 | 12.18 | 15.28 | 11.15 | 16.89 | 14.01 | 15.01 | 10.80 | 13.02 |
| Operating Profit | 1.51 | 2.22 | 1.00 | -1.51 | 2.29 | 1.78 | 1.03 | 1.74 | -4.48 | 0.03 | -0.17 | 0.34 | -0.01 |
| OPM % | 12.22% | 20.73% | 12.22% | -18.24% | 20.00% | 12.75% | 6.32% | 13.50% | -36.10% | 0.21% | -1.15% | 3.05% | -0.08% |
| Other Income | 0.15 | 0.15 | 0.35 | 0.18 | 0.10 | 0.11 | 0.12 | 0.12 | -0.23 | 0.12 | 0.03 | 1.06 | 0.07 |
| Interest | 0.44 | 0.47 | 0.18 | 0.51 | 0.68 | 0.65 | 0.63 | 0.87 | 0.85 | 1.01 | 1.03 | 0.89 | 0.93 |
| Depreciation | 0.30 | 0.29 | 0.58 | 0.46 | 0.55 | 0.57 | 0.61 | 0.62 | 0.62 | 0.63 | 0.66 | 0.64 | 0.70 |
| Profit before tax | 0.92 | 1.61 | 0.59 | -2.30 | 1.16 | 0.67 | -0.09 | 0.37 | -6.18 | -1.49 | -1.83 | -0.13 | -1.57 |
| Tax % | 5.43% | 32.30% | 98.31% | 1.30% | -5.17% | -2.99% | 166.67% | 21.62% | -0.81% | -2.01% | -12.02% | -100.00% | -30.57% |
| Net Profit | 0.88 | 1.09 | 0.01 | -2.33 | 1.22 | 0.69 | -0.25 | 0.29 | -6.13 | -1.46 | -1.61 | 0.01 | -1.08 |
| EPS in Rs | 0.81 | 1.00 | 0.01 | -2.15 | 1.12 | 0.65 | -0.22 | 0.27 | -5.65 | -1.35 | -1.49 | 0.01 | -0.99 |
Last Updated: January 2, 2026, 7:31 am
Below is a detailed analysis of the quarterly data for Banka Bioloo Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 13.01 Cr.. The value appears strong and on an upward trend. It has increased from 11.14 Cr. (Jun 2025) to 13.01 Cr., marking an increase of 1.87 Cr..
- For Expenses, as of Sep 2025, the value is 13.02 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.80 Cr. (Jun 2025) to 13.02 Cr., marking an increase of 2.22 Cr..
- For Operating Profit, as of Sep 2025, the value is -0.01 Cr.. The value appears to be declining and may need further review. It has decreased from 0.34 Cr. (Jun 2025) to -0.01 Cr., marking a decrease of 0.35 Cr..
- For OPM %, as of Sep 2025, the value is -0.08%. The value appears to be declining and may need further review. It has decreased from 3.05% (Jun 2025) to -0.08%, marking a decrease of 3.13%.
- For Other Income, as of Sep 2025, the value is 0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 1.06 Cr. (Jun 2025) to 0.07 Cr., marking a decrease of 0.99 Cr..
- For Interest, as of Sep 2025, the value is 0.93 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.89 Cr. (Jun 2025) to 0.93 Cr., marking an increase of 0.04 Cr..
- For Depreciation, as of Sep 2025, the value is 0.70 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.64 Cr. (Jun 2025) to 0.70 Cr., marking an increase of 0.06 Cr..
- For Profit before tax, as of Sep 2025, the value is -1.57 Cr.. The value appears to be declining and may need further review. It has decreased from -0.13 Cr. (Jun 2025) to -1.57 Cr., marking a decrease of 1.44 Cr..
- For Tax %, as of Sep 2025, the value is -30.57%. The value appears to be increasing, which may not be favorable. It has increased from -100.00% (Jun 2025) to -30.57%, marking an increase of 69.43%.
- For Net Profit, as of Sep 2025, the value is -1.08 Cr.. The value appears to be declining and may need further review. It has decreased from 0.01 Cr. (Jun 2025) to -1.08 Cr., marking a decrease of 1.09 Cr..
- For EPS in Rs, as of Sep 2025, the value is -0.99. The value appears to be declining and may need further review. It has decreased from 0.01 (Jun 2025) to -0.99, marking a decrease of 1.00.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:35 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 47.86 | 30.46 | 38.75 | 42.35 | 50.00 | 54.18 | 53.03 |
| Expenses | 39.17 | 27.01 | 33.19 | 36.16 | 46.20 | 57.03 | 52.84 |
| Operating Profit | 8.69 | 3.45 | 5.56 | 6.19 | 3.80 | -2.85 | 0.19 |
| OPM % | 18.16% | 11.33% | 14.35% | 14.62% | 7.60% | -5.26% | 0.36% |
| Other Income | 0.45 | 0.58 | 0.48 | 0.71 | 0.49 | 0.05 | 1.28 |
| Interest | 0.83 | 1.56 | 1.79 | 1.79 | 2.66 | 3.79 | 3.86 |
| Depreciation | 0.47 | 0.60 | 0.94 | 1.48 | 2.19 | 2.53 | 2.63 |
| Profit before tax | 7.84 | 1.87 | 3.31 | 3.63 | -0.56 | -9.12 | -5.02 |
| Tax % | 20.66% | -17.65% | 6.04% | 30.03% | 19.64% | -2.41% | |
| Net Profit | 6.23 | 2.20 | 3.11 | 2.54 | -0.67 | -8.91 | -4.14 |
| EPS in Rs | 6.05 | 2.14 | 2.87 | 2.34 | -0.60 | -8.20 | -3.82 |
| Dividend Payout % | 6.60% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -64.69% | 41.36% | -18.33% | -126.38% | -1229.85% |
| Change in YoY Net Profit Growth (%) | 0.00% | 106.05% | -59.69% | -108.05% | -1103.47% |
Banka Bioloo Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 3% |
| 3 Years: | 12% |
| TTM: | -4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -551% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 5% |
| 1 Year: | -34% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -1% |
| 3 Years: | -6% |
| Last Year: | -24% |
Last Updated: September 5, 2025, 12:35 am
Balance Sheet
Last Updated: February 1, 2026, 12:26 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 4.11 | 10.28 | 10.85 | 10.85 | 10.85 | 10.87 | 10.88 |
| Reserves | 23.92 | 19.75 | 26.66 | 29.25 | 28.87 | 20.64 | 19.74 |
| Borrowings | 11.44 | 11.69 | 18.50 | 16.71 | 25.91 | 34.73 | 32.39 |
| Other Liabilities | 7.30 | 4.64 | 8.04 | 8.39 | 11.80 | 15.92 | 17.11 |
| Total Liabilities | 46.77 | 46.36 | 64.05 | 65.20 | 77.43 | 82.16 | 80.12 |
| Fixed Assets | 4.02 | 5.09 | 6.77 | 10.68 | 15.39 | 15.86 | 25.14 |
| CWIP | -0.00 | -0.00 | 2.42 | 3.43 | 6.51 | 7.64 | -0.00 |
| Investments | -0.00 | 0.02 | 0.05 | 0.06 | 0.02 | 0.04 | 0.08 |
| Other Assets | 42.75 | 41.25 | 54.81 | 51.03 | 55.51 | 58.62 | 54.90 |
| Total Assets | 46.77 | 46.36 | 64.05 | 65.20 | 77.43 | 82.16 | 80.12 |
Below is a detailed analysis of the balance sheet data for Banka Bioloo Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.88 Cr.. The value appears strong and on an upward trend. It has increased from 10.87 Cr. (Mar 2025) to 10.88 Cr., marking an increase of 0.01 Cr..
- For Reserves, as of Sep 2025, the value is 19.74 Cr.. The value appears to be declining and may need further review. It has decreased from 20.64 Cr. (Mar 2025) to 19.74 Cr., marking a decrease of 0.90 Cr..
- For Borrowings, as of Sep 2025, the value is 32.39 Cr.. The value appears to be improving (decreasing). However, Borrowings exceed Reserves, which may signal higher financial risk. It has decreased from 34.73 Cr. (Mar 2025) to 32.39 Cr., marking a decrease of 2.34 Cr..
- For Other Liabilities, as of Sep 2025, the value is 17.11 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 15.92 Cr. (Mar 2025) to 17.11 Cr., marking an increase of 1.19 Cr..
- For Total Liabilities, as of Sep 2025, the value is 80.12 Cr.. The value appears to be improving (decreasing). It has decreased from 82.16 Cr. (Mar 2025) to 80.12 Cr., marking a decrease of 2.04 Cr..
- For Fixed Assets, as of Sep 2025, the value is 25.14 Cr.. The value appears strong and on an upward trend. It has increased from 15.86 Cr. (Mar 2025) to 25.14 Cr., marking an increase of 9.28 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.64 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 7.64 Cr..
- For Investments, as of Sep 2025, the value is 0.08 Cr.. The value appears strong and on an upward trend. It has increased from 0.04 Cr. (Mar 2025) to 0.08 Cr., marking an increase of 0.04 Cr..
- For Other Assets, as of Sep 2025, the value is 54.90 Cr.. The value appears to be declining and may need further review. It has decreased from 58.62 Cr. (Mar 2025) to 54.90 Cr., marking a decrease of 3.72 Cr..
- For Total Assets, as of Sep 2025, the value is 80.12 Cr.. The value appears to be declining and may need further review. It has decreased from 82.16 Cr. (Mar 2025) to 80.12 Cr., marking a decrease of 2.04 Cr..
However, the Borrowings (32.39 Cr.) are higher than the Reserves (19.74 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -2.75 | -8.24 | -12.94 | -10.52 | -22.11 | -37.58 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 114.17 | 139.96 | 191.78 | 197.63 | 167.61 | 187.28 |
| Inventory Days | 455.71 | 574.51 | 552.18 | |||
| Days Payable | 198.79 | 207.54 | 262.72 | |||
| Cash Conversion Cycle | 114.17 | 139.96 | 448.69 | 564.60 | 457.07 | 187.28 |
| Working Capital Days | 148.56 | 243.73 | 246.13 | 176.60 | 155.49 | 72.15 |
| ROCE % | 8.45% | 10.44% | 9.61% | 3.43% | -7.61% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -8.21 | -0.60 | 2.39 | 3.02 | 2.14 |
| Diluted EPS (Rs.) | -8.21 | -0.59 | 2.39 | 3.02 | 2.14 |
| Cash EPS (Rs.) | -5.89 | 1.42 | 3.70 | 3.71 | 2.73 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 28.98 | 36.62 | 36.97 | 34.57 | 29.21 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 28.98 | 36.62 | 36.97 | 34.57 | 29.21 |
| Revenue From Operations / Share (Rs.) | 49.82 | 46.09 | 39.04 | 35.73 | 29.62 |
| PBDIT / Share (Rs.) | -2.34 | 3.80 | 6.13 | 5.50 | 3.87 |
| PBIT / Share (Rs.) | -4.67 | 1.78 | 4.76 | 4.63 | 3.29 |
| PBT / Share (Rs.) | -8.42 | -0.49 | 3.34 | 3.02 | 1.82 |
| Net Profit / Share (Rs.) | -8.22 | -0.59 | 2.33 | 2.84 | 2.15 |
| NP After MI And SOA / Share (Rs.) | -8.20 | -0.60 | 2.34 | 2.87 | 2.14 |
| PBDIT Margin (%) | -4.69 | 8.24 | 15.69 | 15.38 | 13.07 |
| PBIT Margin (%) | -9.36 | 3.86 | 12.19 | 12.95 | 11.11 |
| PBT Margin (%) | -16.89 | -1.08 | 8.54 | 8.46 | 6.13 |
| Net Profit Margin (%) | -16.49 | -1.30 | 5.98 | 7.94 | 7.24 |
| NP After MI And SOA Margin (%) | -16.45 | -1.30 | 5.99 | 8.01 | 7.23 |
| Return on Networth / Equity (%) | -28.28 | -1.64 | 6.33 | 8.28 | 7.34 |
| Return on Capital Employeed (%) | -11.46 | 3.71 | 11.06 | 10.70 | 9.10 |
| Return On Assets (%) | -10.85 | -0.84 | 3.89 | 4.85 | 4.75 |
| Long Term Debt / Equity (X) | 0.37 | 0.27 | 0.12 | 0.19 | 0.19 |
| Total Debt / Equity (X) | 1.09 | 0.62 | 0.37 | 0.43 | 0.25 |
| Asset Turnover Ratio (%) | 0.67 | 0.70 | 0.65 | 0.72 | 0.65 |
| Current Ratio (X) | 1.41 | 1.95 | 2.54 | 3.07 | 3.92 |
| Quick Ratio (X) | 1.25 | 1.62 | 1.77 | 2.28 | 3.04 |
| Inventory Turnover Ratio (X) | 7.69 | 4.43 | 0.42 | 0.83 | 1.19 |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 18.65 |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 14.67 |
| Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 81.35 |
| Cash Earning Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 85.33 |
| Interest Coverage Ratio (X) | -0.67 | 1.67 | 4.29 | 3.43 | 2.63 |
| Interest Coverage Ratio (Post Tax) (X) | -1.29 | 0.73 | 2.64 | 2.77 | 2.46 |
| Enterprise Value (Cr.) | 108.47 | 123.33 | 88.05 | 100.63 | 62.50 |
| EV / Net Operating Revenue (X) | 2.00 | 2.47 | 2.08 | 2.60 | 2.05 |
| EV / EBITDA (X) | -42.62 | 29.93 | 13.24 | 16.88 | 15.70 |
| MarketCap / Net Operating Revenue (X) | 1.45 | 2.02 | 1.79 | 2.29 | 2.02 |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 81.34 |
| Price / BV (X) | 2.50 | 2.55 | 1.89 | 2.36 | 2.05 |
| Price / Net Operating Revenue (X) | 1.45 | 2.02 | 1.79 | 2.29 | 2.02 |
| EarningsYield | -0.11 | -0.01 | 0.03 | 0.03 | 0.03 |
After reviewing the key financial ratios for Banka Bioloo Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -8.21. This value is below the healthy minimum of 5. It has decreased from -0.60 (Mar 24) to -8.21, marking a decrease of 7.61.
- For Diluted EPS (Rs.), as of Mar 25, the value is -8.21. This value is below the healthy minimum of 5. It has decreased from -0.59 (Mar 24) to -8.21, marking a decrease of 7.62.
- For Cash EPS (Rs.), as of Mar 25, the value is -5.89. This value is below the healthy minimum of 3. It has decreased from 1.42 (Mar 24) to -5.89, marking a decrease of 7.31.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.98. It has decreased from 36.62 (Mar 24) to 28.98, marking a decrease of 7.64.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 28.98. It has decreased from 36.62 (Mar 24) to 28.98, marking a decrease of 7.64.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 49.82. It has increased from 46.09 (Mar 24) to 49.82, marking an increase of 3.73.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -2.34. This value is below the healthy minimum of 2. It has decreased from 3.80 (Mar 24) to -2.34, marking a decrease of 6.14.
- For PBIT / Share (Rs.), as of Mar 25, the value is -4.67. This value is below the healthy minimum of 0. It has decreased from 1.78 (Mar 24) to -4.67, marking a decrease of 6.45.
- For PBT / Share (Rs.), as of Mar 25, the value is -8.42. This value is below the healthy minimum of 0. It has decreased from -0.49 (Mar 24) to -8.42, marking a decrease of 7.93.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -8.22. This value is below the healthy minimum of 2. It has decreased from -0.59 (Mar 24) to -8.22, marking a decrease of 7.63.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -8.20. This value is below the healthy minimum of 2. It has decreased from -0.60 (Mar 24) to -8.20, marking a decrease of 7.60.
- For PBDIT Margin (%), as of Mar 25, the value is -4.69. This value is below the healthy minimum of 10. It has decreased from 8.24 (Mar 24) to -4.69, marking a decrease of 12.93.
- For PBIT Margin (%), as of Mar 25, the value is -9.36. This value is below the healthy minimum of 10. It has decreased from 3.86 (Mar 24) to -9.36, marking a decrease of 13.22.
- For PBT Margin (%), as of Mar 25, the value is -16.89. This value is below the healthy minimum of 10. It has decreased from -1.08 (Mar 24) to -16.89, marking a decrease of 15.81.
- For Net Profit Margin (%), as of Mar 25, the value is -16.49. This value is below the healthy minimum of 5. It has decreased from -1.30 (Mar 24) to -16.49, marking a decrease of 15.19.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -16.45. This value is below the healthy minimum of 8. It has decreased from -1.30 (Mar 24) to -16.45, marking a decrease of 15.15.
- For Return on Networth / Equity (%), as of Mar 25, the value is -28.28. This value is below the healthy minimum of 15. It has decreased from -1.64 (Mar 24) to -28.28, marking a decrease of 26.64.
- For Return on Capital Employeed (%), as of Mar 25, the value is -11.46. This value is below the healthy minimum of 10. It has decreased from 3.71 (Mar 24) to -11.46, marking a decrease of 15.17.
- For Return On Assets (%), as of Mar 25, the value is -10.85. This value is below the healthy minimum of 5. It has decreased from -0.84 (Mar 24) to -10.85, marking a decrease of 10.01.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.37. This value is within the healthy range. It has increased from 0.27 (Mar 24) to 0.37, marking an increase of 0.10.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.09. This value exceeds the healthy maximum of 1. It has increased from 0.62 (Mar 24) to 1.09, marking an increase of 0.47.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.67. It has decreased from 0.70 (Mar 24) to 0.67, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.41. This value is below the healthy minimum of 1.5. It has decreased from 1.95 (Mar 24) to 1.41, marking a decrease of 0.54.
- For Quick Ratio (X), as of Mar 25, the value is 1.25. This value is within the healthy range. It has decreased from 1.62 (Mar 24) to 1.25, marking a decrease of 0.37.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 7.69. This value is within the healthy range. It has increased from 4.43 (Mar 24) to 7.69, marking an increase of 3.26.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -0.67. This value is below the healthy minimum of 3. It has decreased from 1.67 (Mar 24) to -0.67, marking a decrease of 2.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -1.29. This value is below the healthy minimum of 3. It has decreased from 0.73 (Mar 24) to -1.29, marking a decrease of 2.02.
- For Enterprise Value (Cr.), as of Mar 25, the value is 108.47. It has decreased from 123.33 (Mar 24) to 108.47, marking a decrease of 14.86.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.00. This value is within the healthy range. It has decreased from 2.47 (Mar 24) to 2.00, marking a decrease of 0.47.
- For EV / EBITDA (X), as of Mar 25, the value is -42.62. This value is below the healthy minimum of 5. It has decreased from 29.93 (Mar 24) to -42.62, marking a decrease of 72.55.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.45, marking a decrease of 0.57.
- For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Price / BV (X), as of Mar 25, the value is 2.50. This value is within the healthy range. It has decreased from 2.55 (Mar 24) to 2.50, marking a decrease of 0.05.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.45. This value is within the healthy range. It has decreased from 2.02 (Mar 24) to 1.45, marking a decrease of 0.57.
- For EarningsYield, as of Mar 25, the value is -0.11. This value is below the healthy minimum of 5. It has decreased from -0.01 (Mar 24) to -0.11, marking a decrease of 0.10.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Banka Bioloo Ltd:
- Net Profit Margin: -16.49%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -11.46% (Industry Average ROCE: 9.84%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -28.28% (Industry Average ROE: 14.41%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -1.29
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.25
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 34.15)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -16.49%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Infrastructure - General | A 109, Express Apartments, Hyderabad Telangana 500004 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sanjay Banka | Executive Chairman |
| Mrs. Namita Sanjay Banka | Managing Director |
| Mr. Vishal Murarka | Executive Director & CEO |
| Mr. Akhilesh Kumar Tripathi | Executive Director |
| Mr. Sanjay Kumar Gangwar | Independent Director |
| Dr. Basava Raju Dumpala | Independent Director |
| Mrs. Aparajita Agrawal | Independent Director |
| Mr. Anil Sharma | Independent Director |
FAQ
What is the intrinsic value of Banka Bioloo Ltd?
Banka Bioloo Ltd's intrinsic value (as of 06 February 2026) is ₹55.35 which is 9.41% lower the current market price of ₹61.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹66.8 Cr. market cap, FY2025-2026 high/low of ₹97.9/57.0, reserves of ₹19.74 Cr, and liabilities of ₹80.12 Cr.
What is the Market Cap of Banka Bioloo Ltd?
The Market Cap of Banka Bioloo Ltd is 66.8 Cr..
What is the current Stock Price of Banka Bioloo Ltd as on 06 February 2026?
The current stock price of Banka Bioloo Ltd as on 06 February 2026 is ₹61.1.
What is the High / Low of Banka Bioloo Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Banka Bioloo Ltd stocks is ₹97.9/57.0.
What is the Stock P/E of Banka Bioloo Ltd?
The Stock P/E of Banka Bioloo Ltd is .
What is the Book Value of Banka Bioloo Ltd?
The Book Value of Banka Bioloo Ltd is 28.1.
What is the Dividend Yield of Banka Bioloo Ltd?
The Dividend Yield of Banka Bioloo Ltd is 0.00 %.
What is the ROCE of Banka Bioloo Ltd?
The ROCE of Banka Bioloo Ltd is 7.61 %.
What is the ROE of Banka Bioloo Ltd?
The ROE of Banka Bioloo Ltd is 24.2 %.
What is the Face Value of Banka Bioloo Ltd?
The Face Value of Banka Bioloo Ltd is 10.0.